This site is intended for Healthcare professionals only.
×

Vivimed Labs Q4 consolidated net profit jumps to Rs.115 crore for Financial Year 2017


Vivimed Labs Q4 consolidated net profit jumps to Rs.115 crore for Financial Year 2017

Vivimed Labs consolidated revenue for the quarter came in at Rs. 437 crore, registering 25.9% yoy increase. This was mainly driven by 127% yoy increase in Speciality Chemicals Business.

EBITDA for the quarter rose by 287.5% yoy to Rs. 186 crore with a corresponding margin expansion of 2873 bps. EBITDA margin for the quarter stood at 42.6%. This margin expansion was aided by 23% yoy decrease in cost of material consumed.

The PAT for the quarter came in at Rs. 115 crore, yoy increase of 784.6%. This was due to jump in revenue and also supported by 26% yoy decline in finance cost.

Looking at the full year numbers, we see that revenue jumped by 9% to reach Rs.1461.91 crore while EBITDA rose by 77% to 411.7 crore. Company reported net profit of Rs.221.74 crore, up 165% yoy.

The board has recommended dividend of Rs. 0.40 per share for the face value of Rs. 2 each.

Vivimed Labs Ltd is currently trading at Rs. 118.45, up by 7.4 points or 6.66% from its previous closing of Rs. 111.05 on the BSE.

The scrip opened at Rs. 127.9 and has touched a high and low of Rs. 127.9 and Rs. 117.3 respectively. So far 1507856(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 50 DMA.

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: PRESS RELEASE
0 comment(s) on Vivimed Labs Q4 consolidated net profit jumps to Rs.115 crore for Financial Year 2017

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted